Stock Ratings / Health Care / NAMS / financials

BHVN (46) ZLAB (26) SUPN (56) PGEN (35) ⌘ Pro Terminal →

NewAmsterdam Pharma Company N.V. (NAMS) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$20.76 -1.47% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

NewAmsterdam Pharma Company N.V. (NAMS) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $2.48B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NAMS)Realized 20D OHLCV Swing Band: ±11.9%

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How NAMS Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $14.1M

FY24

Rev $45.6M

FY25

Rev $22.5M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$22.5M	52%	-80%	-$203.0M	-$147.8M	-45%
FY 2024	$45.6M	52%	-80%	-$242.0M	-$158.6M	-45%
FY 2023	$14.1M	52%	-80%	-$177.0M	-$141.2M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NAMS)

✓Walkthrough of NAMS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NAMS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -27.31%⚡ TESTING RESISTANCE

2026-10-30O $20.60H $20.94L $19.78C $20.76VOL 1.14M

RES: $20.88SUP: $16.92SMA50: $22.86SMA200: $29.80

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NAMS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NAMS Butterfly Map → + Track NAMS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -50.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NAMS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NAMS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NAMS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NAMS)

Health Care Rank #696 of 1016 ⚔️ BHVN vs NAMS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NAMS vs. BHVN, ZLAB, SUPN, PGEN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, NewAmsterdam Pharma Company N.V. (NAMS) ranks #696 by composite RQD confidence (38/100, grade D-) and #222 by equity capitalization ($2.48B). Within this direct 5-issuer industry benchmark cohort, NAMS leads on earnings valuation at N/A trailing P/E, while SUPN leads on capital efficiency and profitability with -4.5% ROIC and 89.6% gross margin. SUPN currently holds the highest overall quantitative score in the immediate peer group at 56/100 (D+) compared with NAMS at 38/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NAMS ACTIVE NewAmsterdam Pharma Company N.V.	D-	38/100	—	—	-35.0%	-1.47%	$2.48B	Benchmark Subject
BHVN Biohaven Ltd.	D	46/100	—	—	-35.0%	+6.25%	$2.49B	/bhvn-vs-nams →
ZLAB Zai Lab Limited	E	26/100	—	58.3%	-35.0%	-2.95%	$2.51B	/zlab-vs-nams →
SUPN Supernus Pharmaceuticals Inc.	D+	56/100	—	89.6%	-4.5%	+1.85%	$2.43B	/supn-vs-nams →
PGEN Precigen Inc.	D-	35/100	—	—	-35.0%	+9.21%	$2.38B	/pgen-vs-nams →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001936258

In its most recent audited fiscal period (FY2025, filed 2025-12-31), NewAmsterdam Pharma Company N.V. (NAMS) reported GAAP revenue of $22.5M (-50.6% vs. FY2024 revenue of $45.6M , and +59.7% cumulative change since FY2023) , GAAP net income of -$203.0M, operating cash flow of -$147.8M, and free cash flow of -$147.8M (+6.8% YoY). On the balance sheet, NAMS closed FY2025 with $769.3M in total assets against $0 in total debt (Altman Z-Score: 15.94, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$22.5M	-$203.0M	-$147.8M	-$147.8M	$769.3M	—
FY2024 (FY)	2024-12-31	$45.6M	-$242.0M	-$158.6M	-$158.6M	$864.6M	—
FY2023 (FY)	2023-12-31	$14.1M	-$177.0M	-$141.2M	-$141.2M	—	—

3. NAMS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NAMS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $20.76 (-1.47% 1D, market cap $2.48B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, NAMS ranks #696 in composite RQD confidence.

How does NAMS compare to BHVN and ZLAB in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NAMS carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BHVN (Biohaven Ltd.) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $2.49B) and ZLAB (Zai Lab Limited) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $2.51B). Among the 5-stock peer group, NAMS leads on earnings multiple (N/A) while SUPN leads on capital efficiency (-4.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NAMS?

Per NAMS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001936258), NewAmsterdam Pharma Company N.V. generated $22.5M in revenue (-50.6% YoY), -$203.0M in net income, and -$147.8M in free cash flow against $769.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NAMS trading relative to its 50-day, 200-day, and 52-week technical levels?

NAMS last traded at $20.76 (-1.47% on volume of 1,029,060 shares), positioning the stock -9.19% below its 50-day simple moving average ($22.86) and -30.34% below its 200-day simple moving average ($29.80). Across its 52-week range of $19.13 to $42.21, NAMS sits at the 7.1% percentile with a 14-day RSI of 40.7 (NEUTRAL RANGE) and an implied next-earnings move of ±11.9% ($18.29 to $23.23).